19 February 2019
In-licensed for the greater China region.
ZEVALIN® (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. It is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL). ZEVALIN is also indicated for the treatment of patients with previously untreated follicular non-Hodgkin’s Lymphoma who achieve a partial or complete response to first-line chemotherapy.
ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on the combined effect of a targeted biologic monoclonal antibody augmented with the therapeutic effects of a beta-emitting radioisotope. Please see www.zevalin.com for ZEVALIN product and safety information.
Since ZEVALIN is already approved in the U.S. and marketed by our licensor, CASI expects that gaining approval from local regulatory authorities for commercialization in greater China will require a shorter timeframe than clinical-stage drugs. ZEVALIN is now available in Hong Kong.